Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS

被引：0
|
作者：
Raghavan, Manoj [3 ]
Jenkins, Stephen [1 ,2 ]
Wintrich, Sophie [4 ]
Drayson, Mark [3 ]
Bunce, Chris [3 ]
Culligan, Dominic [5 ]
Kulasekararaj, Austin [6 ,7 ]
Wiseman, Dan [8 ,9 ]
Foster, Bethany [1 ]
Dunn, Janet [1 ]
机构：
[1] Univ Warwick, Coventry, W Midlands, England
[2] Dudley Grp NHS Fdn Trust, Dudley, England
[3] Univ Birmingham, Birmingham, W Midlands, England
[4] MDS UK Support Grp, London, England
[5] Aberdeen Royal Infirm, Aberdeen, Scotland
[6] Kings Coll Hosp London, London, England
[7] Kings Coll London, London, England
[8] CRCUK Manchester, Machester, England
[9] Christie NHS Fdn Trust, Machester, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-EP17
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [31] NGS Evaluation of the Eqol-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS
    Oliva, Esther Natalie
    Mammi, Corrado
    Cuzzola, Maria
    Nannya, Yasuhito
    Kulasekararaj, Austin G.
    D'Errigo, Maria Grazia
    Cannata, Maria Concetta
    Zini, Gina
    Latagliata, Roberto
    Niscola, Pasquale
    Santini, Valeria
    Riva, Marta
    Capodanno, Isabella
    Greve, Sabrina
    Smith, Alexander E.
    Ogawa, Seishi
    BLOOD, 2021, 138
  • [32] Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
    Baron, Frederic
    Suciu, Stefan
    Amadori, Sergio
    Muus, Petra
    Zwierzina, Heinz
    Denzlinger, Claudio
    Delforge, Michel
    Thyss, Antoine
    Selleslag, Dominik
    Indrak, Karel
    Ossenkoppele, Gert
    de Witte, Theo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 529 - 533
  • [33] Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.
    Garcia-Manero, Guillermo
    Silverman, Lewis R.
    Sekeres, Mikkael A.
    Yan, Lucy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-ofConcept Study
    Fattizzo, Bruno
    Vercellati, Cristina
    Marcello, Anna
    Bortolotti, Marta
    Zaninoni, Anna
    Fermo, Elisa
    Bianchi, Paola
    Barcellini, Wilma
    BLOOD, 2022, 140 : 4016 - 4017
  • [35] Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations
    Polprasert, Chantana
    Niparuck, Pimjai
    Rattanathammethee, Thanawat
    Chuncharunee, Suporn
    Kobbuaklee, Sirorat
    Songserm, Kritanan
    Suksusut, Amornchai
    Trithiphen, Sasinipa
    Lanamtieng, Theerin
    Kongkiatkamon, Sunisa
    Chanswangphuwana, Chantiya
    Lawasut, Panisinee
    Bunworasate, Udomsak
    Rojnuckarin, Ponlapat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : E293 - E299
  • [36] LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT MUTATIONS ARE AS GOOD AS IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS)
    Polprasert, C.
    Niparuck, P.
    Rattanathammethee, T.
    Chuncharunee, S.
    Kobbualkee, S.
    Songserm, K.
    Suksusut, A.
    Trithiphen, S.
    Lanamtieng, T.
    Kongkiatkamon, S.
    Bunworasate, U.
    Rojnuckarin, P.
    LEUKEMIA RESEARCH, 2021, 108 : S14 - S14
  • [37] THE COST OF BLOOD TRANSFUSION IN LOW-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): AN ECONOMIC ANALYSIS FOR THE CASE OF GREECE
    Fragoulakis, B.
    Maniadakis, N.
    Panagiotidis, P.
    HAEMATOLOGICA, 2012, 97 : 145 - 146
  • [38] A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome.
    Gabrilove, J
    Paquette, R
    Lyons, R
    Mushtaq, C
    Sekeres, M
    Lam, H
    Dreiling, L
    BLOOD, 2005, 106 (11) : 714A - 714A
  • [39] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Eric J. Feldman
    Current Hematologic Malignancy Reports, 2011, 6 : 1 - 2
  • [40] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Feldman, Eric J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 1 - 2
12345